# HLA-A*02:01

1 EU-approved indication of 1 drug needs a HLA-A*02:01 result, in 1 tumour type, most of them in uveal melanoma.

## Approved indications by tumour

### Uveal melanoma

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Tebentafusp](https://oncolabels.com/drugs/tebentafusp) (Kimmtrak) | HLA-A*02:01-positive | Monotherapy | Advanced | - |

## Label wording

- **Tebentafusp** (Kimmtrak), Uveal melanoma, advanced: “KIMMTRAK is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/kimmtrak-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/hla-a-02-01